Dipeptidyl-Peptidase IV Inhibitors: all 899 studies that test it

Page 3 of 9. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in JapanCompletedNCT01318083Phase 2/3Results posted
• Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in JapanCompletedNCT01318070Phase 2/3Results posted
• Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)CompletedNCT01296412Phase 3Results posted
• Efficacy and Safety of Alogliptin in Participants With Type 2 DiabetesCompletedNCT01289119Phase 3Results posted
• Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-componentsCompletedNCT01276327Phase 1Results posted
• Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell RecoveryCompletedNCT01272583Not applicableResults posted
• Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in JapanCompletedNCT01263509Phase 2/3Results posted
• Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in JapanCompletedNCT01263496Phase 2Results posted
• Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in JapanCompletedNCT01263483Phase 2/3Results posted
• Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in JapanCompletedNCT01263470Phase 2Results posted
• CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesCompletedNCT01243424Phase 3Results posted
• A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)CompletedNCT01217073Phase 2Results posted
• Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy VolunteersCompletedNCT01216397Phase 1Results posted
• Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin TherapyCompletedNCT01215097Phase 3Results posted
• Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic ControlCompletedNCT01214239Phase 3Results posted
• Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 DiabetesCompletedNCT01204775Phase 3Results posted
• Comprehensive Add on Study in JapanCompletedNCT01204294Phase 3Results posted
• Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and SulfonylureaCompletedNCT01195090Phase 4Results posted
• Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-studyCompletedNCT01194830Phase 3Results posted
• Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XRCompletedNCT01192152Phase 1Results posted
• Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)CompletedNCT01192139Phase 1Results posted
• Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)CompletedNCT01189890Phase 3Results posted
• Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of FoodCompletedNCT01189201Phase 1Results posted
• Sitagliptin Therapy to Improve Outcomes After Islet AutotransplantCompletedNCT01186562Phase 4Results posted
• START-J: SiTAgliptin in eldeRly Trial in JapanCompletedNCT01183104Not applicableResults posted
• 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 WeeksCompletedNCT01183013Phase 3Results posted
• Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)CompletedNCT01177384Phase 3Results posted
• Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 DiabetesCompletedNCT01155284Phase 2Results posted
• Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)CompletedNCT01131182Phase 4Results posted
• A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263CompletedNCT01128621Phase 2Results posted
• Saxagliptin Triple Oral TherapyCompletedNCT01128153Phase 3Results posted
• A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and PharmacodynamicsCompletedNCT01119846Phase 2Results posted
• The Role of P-glycoprotein in Sitagliptin Clinical PharmacologyCompletedNCT01112670Phase 4Results posted
• Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes MedicationsCompletedNCT01107886Phase 4Results posted
• Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin TreatmentCompletedNCT01099618Phase 4Results posted
• A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.CompletedNCT01098539Phase 3Results posted
• Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)CompletedNCT01093794Phase 1Results posted
• Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIVCompletedNCT01093651Phase 2/3Results posted
• The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes MellitusCompletedNCT01092663Not applicableResults posted
• Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)CompletedNCT01088711Phase 1Results posted
• Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal ImpairmentCompletedNCT01087502Phase 3Results posted
• Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 DiabetesCompletedNCT01084005Phase 3Results posted
• The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) TrialCompletedNCT01081834Phase 3Results posted
• Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)CompletedNCT01076088Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)CompletedNCT01076075Phase 3Results posted
• Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes MellitusCompletedNCT01072331Phase 3Results posted
• Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-AdministeredCompletedNCT01068743Phase 1Results posted
• Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy ParticipantsCompletedNCT01068717Phase 1Results posted
• Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With InsulinCompletedNCT01046110Phase 3Results posted
• A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)CompletedNCT01034111Phase 3Results posted
• 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)CompletedNCT01028391Phase 3Results posted
• Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 DiabetesCompletedNCT01023581Phase 3Results posted
• Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on MetforminCompletedNCT01006603Phase 4Results posted
• Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 DiabetesCompletedNCT01006590Phase 4Results posted
• DPP-4 Inhibition and TZD for DM PreventionTerminatedNCT01006018Not applicableResults posted
• Monotherapy Study of MP-513 in Patients With Type 2 DiabetesCompletedNCT00998881Phase 3Results posted
• Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With PioglitazoneCompletedNCT00996658Phase 3Results posted
• Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin AloneCompletedNCT00995345Phase 2Results posted
• Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)CompletedNCT00993187Phase 4Results posted
• Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 DiabetesCompletedNCT00974090Phase 3Results posted
• Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary SyndromeCompletedNCT00968708Phase 3Results posted
• Prevention of Cystic Fibrosis DiabetesTerminatedNCT00967798Phase 3Results posted
• An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 DiabetesCompletedNCT00960076Phase 3Results posted
• Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes MellitusCompletedNCT00957268Phase 1Results posted
• Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 DiabetesCompletedNCT00954447Phase 3Results posted
• Study of Multiple Doses of Saxagliptin (BMS-477118)CompletedNCT00950599Phase 2Results posted
• Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)TerminatedNCT00947011Phase 2Results posted
• Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney TransplantationTerminatedNCT00936663Phase 4Results posted
• Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)CompletedNCT00929201Phase 1Results posted
• Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic ControlCompletedNCT00918879Phase 3Results posted
• Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mgCompletedNCT00918138Phase 3Results posted
• Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg BidCompletedNCT00915772Phase 3Results posted
• Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)CompletedNCT00899470Phase 1Results posted
• Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)CompletedNCT00897390Phase 1Results posted
• A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)CompletedNCT00888238Phase 1Results posted
• Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient IngestionCompletedNCT00885638Phase 4Results posted
• Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes MellitusCompletedNCT00885378Phase 3Results posted
• Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)CompletedNCT00885352Phase 3Results posted
• Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)CompletedNCT00875394Phase 3Results posted
• A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus MetforminCompletedNCT00870194Phase 4Results posted
• Sitagliptin Umbilical Cord Blood Transplant StudyCompletedNCT00862719Phase 2Results posted
• Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes MellitusCompletedNCT00856284Phase 3Results posted
• Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension TrialCompletedNCT00851903Phase 3Results posted
• Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 DiabetesTerminatedNCT00837759Phase 2Results posted
• MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)CompletedNCT00837577Phase 3Results posted
• ALPHA Sitagliptin Add on to Metformin (0431-103)CompletedNCT00833027Phase 4Results posted
• The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)TerminatedNCT00832624Phase 4Results posted
• Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)CompletedNCT00832390Phase 4Results posted
• A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)CompletedNCT00830076Phase 1Results posted
• Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DMCompletedNCT00820573Phase 4Results posted
• Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea DrugCompletedNCT00819091Phase 3Results posted
• A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)CompletedNCT00813995Phase 3Results posted
• Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background InclusiveCompletedNCT00800683Phase 3Results posted
• Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial DesignCompletedNCT00798161Phase 3Results posted
• Incretin Effect in People With Impaired Fasting GlucoseCompletedNCT00795275Not applicableResults posted
• Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)CompletedNCT00790205Phase 3Results posted
• Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell MassCompletedNCT00775684Not applicableResults posted
• Incretin Effect and Use After Clinical Islet TransplantationCompletedNCT00768651Phase 2Results posted
• Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)CompletedNCT00758069Phase 2Results posted
• Safety and Efficacy of Saxagliptin Plus Insulin With or Without MetforminCompletedNCT00757588Phase 3Results posted

← Dipeptidyl-Peptidase IV Inhibitors overview